Accretion Therapeutics, Inc. — SEC Form D Filing
Accretion Therapeutics, Inc. filed an SEC Form D on February 17, 2026, reporting $750K raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- February 17, 2026
- Amount reported
- $750K
- Round stage
- Series A
- Industry
- Pharmaceuticals
- Website
- https://accretionpharma.com/
What the company does
Securities: Simple Agreement for Future Equity (SAFE). Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Access to high-quality pharmaceuticals can be limited in some regions, affecting healthcare outcomes.
Solution
Accretion Pharmaceuticals manufactures safe, effective, and innovative pharmaceutical products to improve access to healthcare.
Verdict
Investors were drawn to Accretion Therapeutics at this moment because the urgency of improving access to high-quality pharmaceuticals aligned with rising healthcare demands, not because the competitive landscape seemed clear. They implicitly bet on a gap in healthcare procurement that could deliver consistent returns through innovation and quality assurance. However, the limited upside lies in the common challenge of navigating regulatory hurdles, which can stifle growth and introduce unpredictability in outcomes.
Source: SEC EDGAR Form D filing